Myelofibrosis Treatment 'Omzara Tablets' Passes First Gate for National Health Insurance Coverage

Reimbursement Criteria Expanded for Eulida Tablets, Camtop Injection, and Others

The treatment for myelofibrosis, 'Omzara Tablets (Momelotinib Hydrochloride Hydrate),' has passed the first hurdle for health insurance coverage.

The Health Insurance Review and Assessment Service announced on the 19th that the 2nd Severe (Cancer) Disease Deliberation Committee set the reimbursement criteria for GlaxoSmithKline's Omzara Tablets.

Health Insurance Review & Assessment Service CI. Provided by Health Insurance Review & Assessment Service, Yonhap News Agency

Omzara Tablets are used to treat primary myelofibrosis in adults with anemia, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.

At the committee meeting, reimbursement criteria were also established for 'Redaga Gel (Chlorambucil Hydrochloride),' a topical treatment for adult patients with early-stage mycosis fungoides cutaneous T-cell lymphoma. Additionally, the reimbursement criteria were expanded for 'Eulida Tablets (Apalutamide),' a treatment for high-risk non-metastatic castration-resistant prostate cancer, and 'Camtop Injection (Irinotecan Hydrochloride),' a treatment for esophageal cancer.

This content was produced with the assistance of AI translation services.